Xintela
0.22 SEK
-0.45 %
Less than 1K followers
XINT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Xintela
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 2.29 | 2.03 | 1.34 | 0.49 | 0.27 | 0.33 | 0.28 |
| Shares | 71.9 | 126.2 | 152.1 | 309.2 | 422.1 | 576.4 | 861.3 |
| Market cap | 164.2 | 256.7 | 204.1 | 150.6 | 113.8 | 189.2 | 244.6 |
| Enterprise value | 163.8 | 234.0 | 194.2 | 142.2 | - | - | - |
| EV/S | 4,310.1 | - | - | - | - | - | - |
| EV/EBITDA | neg. | neg. | neg. | neg. | - | - | - |
| EV/EBIT | neg. | neg. | neg. | neg. | - | - | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 17.61 | 9.30 | 51.71 | 26.05 | 25.98 | -31.80 | -46.39 |
| P/S | 4,320.9 | - | - | - | 1,422.3 | 44.8 | 107.2 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 54.5 % | 56.9 % | 16.0 % | 23.6 % | 23.8 % | -24.0 % | -18.2 % |
| Gearing ratio | - | 39.5 % | - | - | - | - | - |